Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
- PMID: 12231526
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
Erratum in
- Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3552
Abstract
Purpose: Interleukin 13 receptor alpha2-chain (IL-13Ralpha2) has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme. Here we report the identification of a CTL epitope derived from the IL-13Ralpha2.
Experimental design: Mature dendritic cells (DCs) were pulsed with each of the synthetic peptides that were designed, based on a binding affinity-based prediction and a proteosomal cleavage site prediction system, and used to stimulate autologous CD8+ T cells from an HLA-A2+ healthy donor. After four to six cycles of restimulation, the immunoreactivity of the T cells was analyzed for specific IFN-gamma production and CTL reactivity.
Results: Of the five peptides tested, IL-13Ralpha(345-354) (WLPFGFILI) induced a CD8(+) T-cell line that specifically produced IFN-gamma in response to HLA-A2+ T2 cells pulsed with the relevant peptide and lysed these cells. Peptide titration assays demonstrated that half-maximal lysis of IL-13Ralpha(345-354) peptide-reactive CD8(+) T cells required peptide loading concentration of approximately 5 nM. Perhaps most importantly, this CD8(+) T-cell line also displayed lytic activity against the HLA-A2+ human glioma cell lines that express IL-13Ralpha2.
Conclusions: This novel CTL epitope may therefore serve as an attractive component of peptide-based vaccines to treat glioma and as a surrogate marker of T-cell immune responses in patients before and after therapy.
Similar articles
-
Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.Cancer Res. 2006 Jun 1;66(11):5883-91. doi: 10.1158/0008-5472.CAN-06-0363. Cancer Res. 2006. PMID: 16740728
-
Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells.Cancer Lett. 2007 Oct 18;256(1):128-35. doi: 10.1016/j.canlet.2007.07.015. Epub 2007 Aug 23. Cancer Lett. 2007. PMID: 17719173
-
Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.Clin Cancer Res. 2005 May 1;11(9):3446-54. doi: 10.1158/1078-0432.CCR-04-2043. Clin Cancer Res. 2005. PMID: 15867247
-
An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link.Crit Rev Oncog. 1998;9(3-4):255-68. Crit Rev Oncog. 1998. PMID: 10201630 Review.
-
Epitope selection and development of peptide based vaccines to treat cancer.Semin Cancer Biol. 1995 Dec;6(6):329-36. doi: 10.1016/1044-579x(95)90002-0. Semin Cancer Biol. 1995. PMID: 8938271 Review.
Cited by
-
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.J Clin Oncol. 2011 Jan 20;29(3):330-6. doi: 10.1200/JCO.2010.30.7744. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149657 Free PMC article. Clinical Trial.
-
Current vaccine trials in glioblastoma: a review.J Immunol Res. 2014;2014:796856. doi: 10.1155/2014/796856. Epub 2014 Apr 3. J Immunol Res. 2014. PMID: 24804271 Free PMC article. Review.
-
EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.Neoplasia. 2005 Aug;7(8):717-22. doi: 10.1593/neo.05277. Neoplasia. 2005. PMID: 16207473 Free PMC article.
-
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.J Transl Med. 2004 Nov 24;2(1):40. doi: 10.1186/1479-5876-2-40. J Transl Med. 2004. PMID: 15563374 Free PMC article.
-
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575. doi: 10.1158/1078-0432.CCR-06-1576. Clin Cancer Res. 2007. PMID: 17255279 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials